Compile Data Set for Download or QSAR
Report error Found 23 Enz. Inhib. hit(s) with all data for entry = 12917
TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740596(1,8-dimethyl-3-(3-piperidyl)-5-[[(1R)-1- [3- (trif...)
Affinity DataIC50: 33.9nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740601(3-(1-acetyl-4-piperidyl)-5-[[(1R)-1-[3- (difluorom...)
Affinity DataIC50: 35.5nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740598(3-(1-acetyl-3,6-dihydro-2H-pyridin-4-yl)- 1,8-dime...)
Affinity DataIC50: 36.3nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740597(3-(1-acetyl-3-piperidyl)-1,8-dimethyl-5- [[(1R)-1-...)
Affinity DataIC50: 43.7nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740595(1,8-dimethyl-3-(1,2,3,6- tetrahydropyridin-5-yl)-5...)
Affinity DataIC50: 50.1nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740600(1,8-dimethyl-3-(1-methyl-4-piperidyl)-5- [[rac-(1R...)
Affinity DataIC50: 53.7nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740602(5-[[(1R)-1-[2-fluoro-3- (trifluoromethyl)phenyl]et...)
Affinity DataIC50: 57.5nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740593(1-methyl-6-(1-methylcyclopropyl)-4- [[rac-(1R)-1-[...)
Affinity DataIC50: 58.9nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740592(6-cyclopropyl-1-methyl-4-[[(1R)-1-[3- (trifluorome...)
Affinity DataIC50: 63.1nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740581(6-cyclopentyl-1-methyl-4-[[(1R)-1- [3- (trifluorom...)
Affinity DataIC50: 77.6nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740599(1,8-dimethyl-5-[[rac-(1R)-1-[3- (difluoromethyl)ph...)
Affinity DataIC50: 93.3nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740586(6-isopropyl-1-methyl-4-[[(1R)-1-[3- (trifluorometh...)
Affinity DataIC50: 95.5nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740591(3-(cyclopenten-1-yl)-1,8-dimethyl-5- [[(1R)-1-[3- ...)
Affinity DataIC50: 110nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740589(8-methyl-3-[(3S)-tetrahydrofuran-3- yl]oxy-N-[(1R)...)
Affinity DataIC50: 174nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740590(3-(cyclopenten-1-yl)-5-[[(1R)-1-[3- (difluoromethy...)
Affinity DataIC50: 178nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740580(6-cyclopentyl-1-methyl-4-[1-[3- (trifluoromethyl)p...)
Affinity DataIC50: 191nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740587(1-methyl-4-[[rac-(1R)-1-[3- (trifluoromethyl)pheny...)
Affinity DataIC50: 234nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740588(8-methyl-3-[(3S)-tetrahydrofuran-3- yl]oxy-N-[1-[3...)
Affinity DataIC50: 251nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740584(1-methyl-6-(oxetan-3-ylmethyl)-4-[[(1R)- 1-[3- (tr...)
Affinity DataIC50: 302nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740583(6-(cyclopropylmethyl)-1-methyl-4- [[(1R)-1-[3- (tr...)
Affinity DataIC50: 302nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740582(6-ethyl-1-methyl-4-[[(1R)-1-[3- (trifluoromethyl)p...)
Affinity DataIC50: 347nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740585(1-methyl-6-[(3-methyloxetan-3- yl)methyl]-4-[[(1R)...)
Affinity DataIC50: 457nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent

TargetGTPase KRas/Son of sevenless homolog 1 [564-1049](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM740594(5-methyl-2-[(3S)-tetrahydrofuran-3- yl]oxy-N-[1-[3...)
Affinity DataIC50: 676nMAssay Description:The capacity of compounds to inhibit SOS1 binding to KRAS-WT (wild-type) was quantified using a FRET-based protein-protein interaction assay. The ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/16/2025
Entry Details
US Patent